Intra-Cellular Therapies Inc (NASDAQ:ITCI) CFO Sells $513,730.08 in Stock
Intra-Cellular Therapies Inc (NASDAQ:ITCI) CFO Lawrence J. Hineline sold 19,638 shares of Intra-Cellular Therapies stock in a transaction dated Thursday, January 9th. The stock was sold at an average price of $26.16, for a total value of $513,730.08. Following the sale, the chief financial officer now owns 18,800 shares of the company’s stock, valued at approximately $491,808. The transaction was disclosed in a document filed with the SEC, which is available at this link.
NASDAQ:ITCI traded up $0.47 during mid-day trading on Friday, reaching $25.90. The company’s stock had a trading volume of 2,709,342 shares, compared to its average volume of 4,080,563. The company’s fifty day simple moving average is $19.33 and its two-hundred day simple moving average is $11.95. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.77 and a quick ratio of 7.77. Intra-Cellular Therapies Inc has a twelve month low of $6.75 and a twelve month high of $43.56. The stock has a market cap of $1.46 billion, a P/E ratio of -9.12 and a beta of 1.96.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17. Sell-side analysts expect that Intra-Cellular Therapies Inc will post -2.85 EPS for the current fiscal year.
A number of research firms recently commented on ITCI. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research report on Wednesday. Canaccord Genuity lifted their price objective on Intra-Cellular Therapies from $29.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. BidaskClub cut Intra-Cellular Therapies from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. ValuEngine cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, BTIG Research lifted their price objective on Intra-Cellular Therapies from $34.00 to $73.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $36.25.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Read More: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.